{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-032857","form_type":"8-K","ticker":"BTCY","cik":"0001630113","company_name":"BIOTRICITY INC.","filed_at":"2022-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.495436+00:00","generated_at":"2026-06-21T15:52:26.398118+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Biotricity Q2 FY2023 revenue $2.4M, up 14% sequentially; net loss $4.9M","bullets":["Revenue $2.4M, up 14% QoQ; gross profit $1.3M (54% margin).","Net loss $4.9M ($0.094 per share) for quarter ended Sept 30, 2022.","Bioheart monitor won TIME's Best Inventions 2022; awarded $250K NIH grant.","Surpassed 2 billion recorded heartbeats for AFib; launched Biocare Cardiac Disease Management Solution.","Maintained 95%+ customer retention; new distribution partnerships signed."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-032857","json":"https://secwatch.observer/filing/0001493152-22-032857.json","markdown":"https://secwatch.observer/filing/0001493152-22-032857.md","text":"https://secwatch.observer/filing/0001493152-22-032857.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630113/000149315222032857/0001493152-22-032857-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630113/000149315222032857/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T15:52:26.398118+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"56e866e1c65d4592037facf7a2a755a9785ab6f4","claim":"BIOTRICITY INC. reported fiscal 2023 second quarter ended September 30, 2022 results: revenue $2.4 million, net income $4.9 million, EPS $0.094 per share.","evidence_excerpt":"Q2-FY23 Financial Highlights: ● Revenue totaled $2.4 million. ● Gross profit totaled $1.3 million. ● Gross profit margins were 54%. ● Net loss totaled $4.9 million or $0.094 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630113/000149315222032857/0001493152-22-032857-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal 2023 second quarter ended September 30, 2022"},{"label":"Revenue","value":"$2.4 million"},{"label":"Net income","value":"$4.9 million"},{"label":"EPS","value":"$0.094 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}